Nephronophthisis (NPHP) is a recessive tubulointerstitial nephropathy and a leading genetic cause of kidney failure in children and young adults. The most common genetic cause is a homozygous deletion of NPHP1, which encodes nephrocystin-1, a protein essential for primary cilium structure and cell junctions. Using personalized medicine and deep phenotyping, we investigated a family with three siblings carrying a homozygous NPHP1 deletion. We compared kidney biopsy tissue and human urine-derived renal epithelial cells (hURECs) from these individuals. Bulk RNA-seq on patient hURECs revealed altered expression in EGFR signalling, extracellular components and adherens junctions, which is consistent with the known roles for nephrocystin-1. Treatment with alprostadil, a proposed NPHP therapy, increased ciliation but worsened ciliary elongation. By contrast, the EGFR kinase inhibitor AG556 rescued of ciliary length and morphology. Transcriptional profiling post-treatment showed AG556 reversed the disease signature more effectively that alprostadil. These findings suggest that EGFR inhibition might offer a more promising therapeutic strategy for NPHP1-associated renal ciliopathy, warranting further testing in in vivo models before clinical application.
Sudhindar, P. D., Olinger, E., Sentell, Z. T., Mabillard, H., Dicka, B., Wood, K., Rutland, D., Collins, C., Trevisan-Herraz, M., Sayer, J. A., & Arcila-Galvis, J. E. (2025). Urinary renal epithelial cells can be used for NPHP1 phenotyping and a personalized therapeutic strategy. Journal of Cell Science, 138(20 (2025)). https://doi.org/10.1242/jcs.264141 (Original work published 2025)